Page 7 - Thomas Biegi News Today

EQS-News: MorphoSys AG / Key word: Change in Forecast MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 21.10.2022 / 11:41... | October 21, 2022

EQS-News: MorphoSys AG / Key word(s): Change in Forecast MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financi...

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL 28.09.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release BOS...

BOSTON - MorphoSys USA, Inc., a fully owned subsidiary of MorphoSys AG , announced data from the ongoing L-MIND study showing that Monjuvi plus lenalidomide followed by Monjuvi monotherapy provided... | September 29, 2022

DGAP-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys appoints Tim Demuth as new Chief Research and Development Officer, following the retirement of Malte Peters 31.08.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, August 31, 2...

Tim Demuth, M.D., Ph.D., has more than 20 years of broad leadership experience in drug development, with a focus in oncology MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Malte Peters

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys appoints Tim Demuth as new Chief Research and Development Officer, fol...

DGAP-News: MorphoSys AG / Key word(s): Half Year Results MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results ...

DGAP-News: MorphoSys AG / Key word(s): Half Year Results MorphoSys AG: Invitation to MorphoSys Second Quarter and First Half Year 202...

Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million)Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million)Update of